- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- SUN PHARMA - LUPIN LTD
SUN PHARMA vs LUPIN LTD - Comparison Results
SUN PHARMA 
Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
LUPIN LTD
Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More
Current Valuations
| SUN PHARMA | LUPIN LTD | SUN PHARMA/ LUPIN LTD |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 25.8 | 41.9 | 61.6% | View Chart |
| P/BV | x | 2.7 | 2.6 | 105.3% | View Chart |
| Dividend Yield | % | 0.5 | 0.6 | 72.2% |
Financials
 SUN PHARMA  LUPIN LTD |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-18 |
LUPIN LTD Mar-18 |
SUN PHARMA/ LUPIN LTD |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 701 | 1,465 | 47.8% | |
| Low | Rs | 433 | 727 | 59.6% | |
| Sales per share (Unadj.) | Rs | 110.4 | 349.6 | 31.6% | |
| Earnings per share (Unadj.) | Rs | 11.0 | 5.6 | 197.5% | |
| Cash flow per share (Unadj.) | Rs | 17.2 | 29.6 | 58.3% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 5.00 | 40.0% | |
| Dividend yield (eoy) | % | 0.4 | 0.5 | 77.3% | |
| Book value per share (Unadj.) | Rs | 158.8 | 300.3 | 52.9% | |
| Shares outstanding (eoy) | m | 2,399.26 | 452.08 | 530.7% | |
| Bonus/Rights/Conversions | - | ESOPS | - | ||
| Price / Sales ratio | x | 5.1 | 3.1 | 163.8% | |
| Avg P/E ratio | x | 51.6 | 197.2 | 26.2% | |
| P/CF ratio (eoy) | x | 32.9 | 37.1 | 88.8% | |
| Price / Book Value ratio | x | 3.6 | 3.6 | 97.8% | |
| Dividend payout | % | 18.2 | 90.0 | 20.3% | |
| Avg Mkt Cap | Rs m | 1,360,021 | 495,502 | 274.5% | |
| No. of employees | `000 | 17.8 | 17.0 | 104.4% | |
| Total wages/salary | Rs m | 53,671 | 28,647 | 187.4% | |
| Avg. sales/employee | Rs Th | 14,890.9 | 9,273.6 | 160.6% | |
| Avg. wages/employee | Rs Th | 3,017.1 | 1,681.0 | 179.5% | |
| Avg. net profit/employee | Rs Th | 1,480.6 | 147.4 | 1,004.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 264,895 | 158,042 | 167.6% | |
| Other income | Rs m | 8,388 | 1,504 | 557.9% | |
| Total revenues | Rs m | 273,282 | 159,545 | 171.3% | |
| Gross profit | Rs m | 56,081 | 31,475 | 178.2% | |
| Depreciation | Rs m | 14,998 | 10,859 | 138.1% | |
| Interest | Rs m | 5,176 | 2,044 | 253.3% | |
| Profit before tax | Rs m | 44,295 | 20,076 | 220.6% | |
| Minority Interest | Rs m | 0 | -71 | 0.0% | |
| Prior Period Items | Rs m | 0 | 35 | 0.0% | |
| Extraordinary Inc (Exp) | Rs m | -9,505 | -14,644 | 64.9% | |
| Tax | Rs m | 8,452 | 2,885 | 293.0% | |
| Profit after tax | Rs m | 26,338 | 2,513 | 1,048.2% | |
| Gross profit margin | % | 21.2 | 19.9 | 106.3% | |
| Effective tax rate | % | 19.1 | 14.4 | 132.8% | |
| Net profit margin | % | 9.9 | 1.6 | 625.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 316,359 | 122,095 | 259.1% | |
| Current liabilities | Rs m | 198,643 | 50,956 | 389.8% | |
| Net working cap to sales | % | 44.4 | 45.0 | 98.7% | |
| Current ratio | x | 1.6 | 2.4 | 66.5% | |
| Inventory Days | Days | 95 | 85 | 112.1% | |
| Debtors Days | Days | 108 | 120 | 89.8% | |
| Net fixed assets | Rs m | 213,178 | 129,876 | 164.1% | |
| Share capital | Rs m | 2,399 | 904 | 265.4% | |
| "Free" reserves | Rs m | 378,606 | 134,866 | 280.7% | |
| Net worth | Rs m | 381,006 | 135,771 | 280.6% | |
| Long term debt | Rs m | 17,721 | 64,245 | 27.6% | |
| Total assets | Rs m | 643,028 | 263,054 | 244.4% | |
| Interest coverage | x | 9.6 | 10.8 | 88.3% | |
| Debt to equity ratio | x | 0 | 0.5 | 9.8% | |
| Sales to assets ratio | x | 0.4 | 0.6 | 68.6% | |
| Return on assets | % | 4.9 | 1.7 | 283.0% | |
| Return on equity | % | 6.9 | 1.9 | 373.5% | |
| Return on capital | % | 10.0 | 3.7 | 269.4% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 40,816 | 53,141 | 76.8% | |
| Fx outflow | Rs m | 30,143 | 19,335 | 155.9% | |
| Net fx | Rs m | 10,673 | 33,807 | 31.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 39,072 | 17,512 | 223.1% | |
| From Investments | Rs m | -33,708 | -14,073 | 239.5% | |
| From Financial Activity | Rs m | -15,393 | -14,921 | 103.2% | |
| Net Cashflow | Rs m | -7,359 | -11,482 | 64.1% | |
Share Holding
| Indian Promoters | % | 63.7 | 46.6 | 136.7% | |
| Foreign collaborators | % | 0.0 | 0.2 | - | |
| Indian inst/Mut Fund | % | 5.1 | 11.3 | 45.4% | |
| FIIs | % | 23.0 | 31.9 | 72.1% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 8.3 | 10.1 | 82.2% | |
| Shareholders | 133,026 | 98,259 | 135.4% | ||
| Pledged promoter(s) holding | % | 0.5 | 0.0 | - |
Compare SUN PHARMA With: PLETHICO PHARMA BIOCON LTD J.B.CHEMICALS ALKEM LABORATORIES AJANTA PHARMA
Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Recapitalisation Package for PSBs: The Pros & Cons(Podcast)
Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.
Related Views on News
LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.
SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)
Nov 14, 2018 | Updated on Nov 14, 2018For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)
Nov 6, 2018 | Updated on Nov 6, 2018For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.
More Views on NewsMost Popular
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)
Feb 12, 2019Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.
The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)
Feb 15, 2019Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.
More|
| |
SUN PHARMA SHARE PRICE
Feb 22, 2019 (Close)
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA - GSK PHARMA COMPARISON
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.